ESMO 2017 | The importance of the OlympiA trial for breast cancer patients
Elzbieta Senkus-Konefka, MD, PhD from the Medical University of Gdansk, Gdansk, Poland talks to us about the OlympiA study (NCT02032823), a Phase III clinical trial which assessed the efficacy of the PARP inhibitor olaparib in the treatment of breast cancer patients with germline BRCA 1/2 mutations. Dr Senkus-Konefa discusses the importance of this trial and talks us through the results, sharing her hopes for what olaparib could mean for breast cancer patients. This interview was recorded at the 2017 European Society for Medical Oncology (ESMO) conference held in Madrid, Spain.
Get great new content delivered to your inboxSign up